Tests RO7656594 safety in advanced prostate cancer
Tests the drug RO7656594 for safety in adults with advanced prostate cancer.
Key facts
- Who runs it
- Genentech, Inc.
- Where
- Chicago, Nashville, New Haven, Orlando, and Scottsdale, United StatesSee the 5 sitesAlso in 6 other countries, 21 sites
- Trial code
- Registry title
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 210 people, planned
- Started
- 2 May 2023
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- RO7656594
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread. They must already have had certain earlier treatments. The trial tests the safety and early activity of a new drug, RO7656594.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic prostate adenocarcinoma, without small-cell carcinoma or neuroendocrine features. ECOG performance status of 1 or lower.
- Earlier treatment
- Must have had a second-generation androgen receptor (AR)-targeted therapy such as abiraterone, enzalutamide, apalutamide or darolutamide. Must have had a taxane regimen, or be considered ineligible for one, or have refused one. With a known BRCA1 or BRCA2 mutation: must have had a PARP inhibitor, or be considered ineligible for one, if approved and available.
- Biomarker or test result
- No specific marker is required. People with a known pathogenic BRCA1 or BRCA2 mutation have an extra treatment condition.
Main reasons for not taking part
- Approved cancer drug treatment within 14 days or 5 drug half-lives (whichever is longer, up to 28 days) before the first study treatment
- Any investigational agent within 28 days before the first study treatment
- Any previous AR protein degrader treatment
- Untreated central nervous system (CNS) metastases or leptomeningeal disease
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Metastatic prostate adenocarcinoma without small-cell carcinoma or neuroendocrine features
- Prior therapy with a second-generation androgen receptor (AR)-targeted therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide)
- Prior therapy with a taxane regimen or are considered ineligible for treatment with a taxane regimen or have refused treatment with a taxane regimen, unless otherwise specified
- For participants with a known pathogenic breast cancer gene 1 (BRCA1) or BRCA2 mutation: prior therapy with a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor, or are considered ineligible for treatment with a PARP inhibitor, if such therapy is approved and available
Who cannot take part
- Treatment with any approved systemic anti-cancer therapy within 14 days or 5 drug elimination half-lives (whichever is longer, not to exceed 28 days) prior to the first study treatment
- Treatment with any investigational agent within 28 days prior to the first study treatment
- Treatment with any previous AR protein degrader
- Untreated central nervous system (CNS) metastases or leptomeningeal disease; Note: Other protocol specified inclusion/exclusion criteria may apply
Where in United States
Also in 6 other countries, 21 sites
- University of Illinois Hospital & Health Sciences SystemChicago, United StatesTaking people
- SCRI Oncology PartnersNashville, United StatesTaking people
- Yale Cancer CenterNew Haven, United StatesTaking people
- Sarah Cannon Research Institute @ Florida CancerOrlando, United StatesTaking people
- HonorHealthScottsdale, United StatesTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.
The 2 groups in the trial
- Stage 1: Dose EscalationTreatment being tested
Participants will receive RO7656594 administered at a specified dose on specific days in each 28-day cycle. The dose will be increased in successive cohorts until a study-specific threshold is reached.
Treatment: RO7656594
- Stage 2: ExpansionTreatment being tested
Participants will receive RO7656594 at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD).
Treatment: RO7656594
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer
- Plain-language title
- Tests RO7656594 safety in advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 November 2026